Novo Nordisk shares see a dip: what is pressuring the stock

Traders Union
All News
Financial News
Novo nordisk slides 2.35% today

Highlights

Novo Nordisk has repurchased approximately 6.58 million B shares for DKK 1.78 billion as part of its ongoing DKK 15 billion buyback programme.
Progress on shareholder returns contrasts with a setback for CagriSema in phase 3 trials and ongoing legal scrutiny, contributing to sustained selling pressure.
Technical indicators confirm a strong bearish trend with Novo Nordisk expected to trade narrowly between $36.31 and $36.39, with a decisive move below $36.31 triggering further downside risk.

Buyback progress offset by clinical disappointment and legal scrutiny

Novo Nordisk reported progress on its DKK 15 billion share buyback program, having repurchased 6,577,992 B shares at an average price of DKK 271.14 as of March 13, 2026, amounting to approximately DKK 1.78 billion held in treasury stock. The buyback is intended to support shareholder value and is carried out under EU Market Abuse Regulation safe harbor provisions. There was also a setback in the clinical development of CagriSema, which underperformed in a key phase 3 trial and attracted legal scrutiny, though price action has remained under broader selling pressure.

Anton Kharitonov, expert at Traders Union, sees Novo Nordisk A/S locked in a pronounced bearish trend. The persistent failure to reclaim any moving average signals continued technical weakness. He notes that the share buyback provides limited fundamental relief, as legal and clinical setbacks further dampen sentiment. Oscillators highlight oversold conditions, but he argues the absence of dynamic support leaves the stock vulnerable. "Despite a technical oversold state, I consider any near-term rebound fragile until we see a sustained move above $43.16," he says.

Viktoras Karapetjanc, expert at Traders Union, believes the long-term fundamental story for Novo Nordisk remains promising despite short-term setbacks. He views the large share buyback as evidence of management's forward-looking approach to boosting shareholder value. Recent volatility presents a chance for patient investors as the underlying market structure is intact. "I see further growth potential once sentiment stabilizes, and the current price offers multiple opportunity setups for the disciplined," he affirms.

Bearish momentum persists amid oversold signals and gap down

The stock is trading well below the key moving averages (MA-20, MA-50, and MA-200), indicating sustained selling momentum. Dynamic resistance is noted at the Ichimoku Kijun level of $43.16, while immediate dynamic support is absent. Oscillators including RSI, Stoch RSI, and CCI point to oversold conditions, and momentum indicators like ADX and MACD confirm a pronounced bearish trend. BBP remains negative, price action sits mid-range within today’s $36.39–$36.86 band after a notable gap down, and weak AO readings underscore continued downward momentum.

Previously it was reported that Novo Nordisk faced persistent bearish momentum amid negative technical signals and regulatory concerns following clinical trial setbacks. This updated analysis strengthens that view, as intensified selling pressure and deepening oversold signals highlight the importance of monitoring the $36.31 support level for any potential escalation of downside risk.

Source of Data: NVO Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.